Vertex Pharmaceuticals (VRTX) Just Reclaimed the 200-Day Moving AverageZacks Investment Research • 12/02/21
Vertex Pharmaceuticals (VRTX) Recently Broke Out Above the 20-Day Moving AverageZacks Investment Research • 12/02/21
Vertex Announces Positive Results From Phase 2 Study of VX-147 in APOL1-Mediated Focal Segmental GlomerulosclerosisBusiness Wire • 12/01/21
Vertex Announces Reimbursement Agreement in Spain for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat People With Cystic Fibrosis 12 Years and Older With At Least One F508del Mutation in the CFTR GeneBusiness Wire • 11/19/21
Vertex Receives CHMP Positive Opinion for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor in Children With Cystic Fibrosis Ages 6 Through 11Business Wire • 11/12/21
Wall Street Analysts Think Vertex (VRTX) Could Surge 36%: Read This Before Placing a BetZacks Investment Research • 11/08/21